Search results for: Kenneth Arrow
Filter search results
Around The World in HTAs: Spain – Are We There Yet?
15 March 2023
…the CIPM. Current challenges The standard process to evaluate pharmaceutical products gives a narrow time window of 10 days for REvalMed to conduct the economic evaluation of the new drug,…
Why Care About Health Inequality?
1 January 2001
…illness; to improve the health of the worst off in society and to narrow the health gap. This monograph looks at health inequalities in the UK from a health economics…
Looking Further Afield – What Can Health Economics Learn from the Environmental Economics Approach to Discounting?
1 February 2024
…and Opoku, E.E.O., 2023. Environmental degradation and economic growth: Investigating linkages and potential pathways. Energy Economics, 123, p.106734. 10.1016/j.eneco.2023.106734. Arrow, K., Cropper, M., Gollier, C., Groom, B., Heal, G., Newell,…
What the first EU JCA reveals about assessing precision oncology
28 July 2026
…assessment populations requiring separate comparative evidence, setting the stage for the evidence-generation challenges explored below. The risk is that greater precision becomes equated with assessing each increasingly narrow population entirely in isolation. An analogy is a…
Employer Costs from Respiratory Infections
16 December 2024
Share this: Download publication Helen Hayes Brittany Darrow Lotte Steuten Graham Cookson Amanda Cole Our latest research shows respiratory infections cost UK businesses £44 billion a year. Workplace vaccination programs…
The Importance of Diversity of Supply in Rare Diseases Markets
23 January 2025
Share this: Download publication Matthew Napier Brittany Darrow Matthias Hofer Mikel Berdud Amanda Cole Rare disease medicine markets often rely on single suppliers, increasing the risk of shortages and limiting…
Consolidation and Competition in the Pharmaceutical Industry
9 January 2001
…becoming a key policy issue alongside the traditional concern with competition between existing products in final markets. Yarrow makes another key point, which is that the need for the additional…
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
…footprint compared to shorter- acting alternatives. Realising the potential value of long-acting therapies is currently hindered by a narrow view of value in health technology assessment (HTA) and variability across…
Advancing Rare Disease Care: Challenges and Key Issues
28 February 2025
…update makes some of the routing criteria more explicit, eligibility continues to apply to only a narrow subset of rare disease treatments. The graph below demonstrates that – for orphan…